Persian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
adrenocortical carcinoma/خستگی پزشکی
پیوند در کلیپ بورد ذخیره می شود
صفحه 1 از جانب 17 نتایج
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند
ورود به سیستم / ثبت نام
BACKGROUND
Adrenocortical carcinoma (ACC) is rare, nearly always fatal, and to the authors' knowledge has few nonsurgical treatment options. Based on in vitro studies demonstrating the efficacy of mitotane as a P-glycoprotein (Pgp) antagonist, and expression of high levels of Pgp in ACC, the authors
[Central nervous system metastasis from non-functioning adrenocortical carcinoma: report of a case].
فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند
ورود به سیستم / ثبت نام
We report a rare case of brain tumor metastasizing from an adrenocortical carcinoma. A 47-year-old man was referred to our department on September 21, 1995, with complaints of episodic loss of consciousness and severe left motor weakness. There was a past history of left adrenalectomy performed in
Suprarenal retroperitoneal liposarcoma with intracaval tumor thrombus: an imaging mimic of adrenocortical carcinoma.
فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند
ورود به سیستم / ثبت نام
We report a 57-year-old previously healthy man who presented with dull right upper quadrant pain, weight loss, fatigue, and night sweats. Computed tomography demonstrated a large, heterogeneously enhancing, soft tissue mass with no macroscopic fat above the right kidney with tumor thrombus extending
[Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels].
فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند
ورود به سیستم / ثبت نام
BACKGROUND
o,p'-DDD (1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-ethane), which leads to a cytotoxic necrosis of the adrenal glands, currently is therapy of choice for metastasized adrenocortical carcinomas. Clinical experience is still poor, but most studies demonstrate an increment of
[Adrenal cortical carcinoma (ACC)--report of 10 cases].
فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند
ورود به سیستم / ثبت نام
Ten patients with adrenal cortical carcinoma were treated from 1966 to 1986. There were 7 males and 3 females. The typical clinical manifestations, marked increase of 17-ketosteroid, 17-hydroxycorticoids and DHA, and negative dexamethasone suppression test were essential for the diagnosis. Of the
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.
فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند
ورود به سیستم / ثبت نام
OBJECTIVE
Insulin-like growth factor 1 receptor signaling through upregulation of the stimulatory ligand IGF-II has been implicated in the pathogenesis of adrenocortical carcinoma. As there is a paucity of effective therapies, this dose expansion cohort of a phase 1 study was undertaken to determine
Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry.
فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند
ورود به سیستم / ثبت نام
OBJECTIVE
Adrenocortical carcinoma (ACC) is a rare malignancy with a dismal prognosis. In advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary and salvage treatments are warranted.
METHODS
Retrospective cohort study of participants in the prospective European
Adjuvant radiotherapy after surgical resection for adrenocortical carcinoma: A systematic review of observational studies and meta-analysis.
فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند
ورود به سیستم / ثبت نام
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.
فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند
ورود به سیستم / ثبت نام
BACKGROUND
Adrenocortical carcinoma is a rare, aggressive cancer for which few treatment options are available. Linsitinib (OSI-906) is a potent, oral small molecule inhibitor of both IGF-1R and the insulin receptor, which has shown acceptable tolerability and preliminary evidence of anti-tumour
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.
فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند
ورود به سیستم / ثبت نام
BACKGROUND
There is a strong rationale in the use of antiangiogenic therapy in the management of adrenocortical carcinoma (ACC). Metronomic administration of chemotherapy and antiangiogenic drugs can be synergistic in targeting endothelial cells.
OBJECTIVE
We assessed the activity of sorafenib plus
Feminizing Adrenocortical Carcinoma Without Gynecomastia.
فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند
ورود به سیستم / ثبت نام
Malignant feminizing adrenocortical tumors are exceedingly rare. Their main presentation is gynecomastia. In these estrogen secreting tumors (with or without other adrenocortical hormones) lack of gynecomastia is exceptional as in our case. A 44-year-old man presented with abdominal pain.
Is there a role of targeted agents in the management of adrenocortical cancers?
فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند
ورود به سیستم / ثبت نام
Background. Adrenocortical carcinoma (ACC) is a rare and aggressive tumor arising from the adrenal cortex with an incidence of one to two cases per million within the general US population. Recent developments in the understanding of the pathogenesis of ACC have led to multiple clinical trials
A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.
فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند
ورود به سیستم / ثبت نام
BACKGROUND
Patients with advanced endocrine cancers, such as adrenocortical carcinoma and medullary thyroid carcinoma, have few well-validated therapeutic options. Pre-clinical studies have suggested potential activity of imatinib in these tumors. We therefore sought to establish a safe, novel
Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.
فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند
ورود به سیستم / ثبت نام
OBJECTIVE
A phase I trial was performed with combretastatin A4 phosphate (CA4P), a novel tubulin-binding agent that has been shown to rapidly reduce blood flow in animal tumors.
METHODS
The drug was delivered by a 10-minute weekly infusion for 3 weeks followed by a week gap, with intrapatient dose
Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.
فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند
ورود به سیستم / ثبت نام
OBJECTIVE
We determined the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics, and preliminary activity of OSI-906, a potent, oral, dual inhibitor of insulin-like growth factor-1 receptor (IGF1R) and insulin receptor (IR), in patients with advanced solid tumors.
METHODS
This
کاملترین پایگاه داده گیاهان دارویی با پشتیبانی علمی
- به 55 زبان کار می کند
- درمان های گیاهی با پشتوانه علم
- شناسایی گیاهان توسط تصویر
- نقشه GPS تعاملی - گیاهان را در مکان نشان دهید (به زودی)
- انتشارات علمی مربوط به جستجوی خود را بخوانید
- گیاهان دارویی را با توجه به اثرات آنها جستجو کنید
- علایق خود را سازماندهی کنید و با تحقیقات اخبار ، آزمایشات بالینی و حق ثبت اختراع در جریان باشید
علامت یا بیماری را تایپ کنید و در مورد گیاهانی که ممکن است به شما کمک کنند ، بخوانید ، یک گیاه تایپ کنید و بیماری ها و علائمی را که در برابر آن استفاده می شود ، ببینید.
* کلیه اطلاعات براساس تحقیقات علمی منتشر شده است
